Filed by RadNet, Inc.
Filing pursuant to Rule 425 under the
Securities Act of 1933, as amended
Deemed filed under Rule 14a-12 under the
Securities Exchange Act of 1934, as amended
Subject Company: iCAD Inc.
Commission File Number: 001-09341
Explanatory Note: The following speaking points were shared with
RadNet, Inc. employees.
| · | I am pleased to share that RadNet has entered into a definitive agreement to acquire iCAD, a global leader in clinically proven AI-powered
breast health solutions. |
| | |
| | The transaction, expected to close in the
second or third quarter of 2025, is subject to approval by iCAD stockholders and other customary closing conditions. |
| | |
| · | This marks an exciting milestone in our mission to advance breast health by addressing clinical and operational
challenges in high-volume care settings through the power of AI and imaging. The acquisition aims to create a comprehensive portfolio
of diagnostic AI, personalized risk assessment, and integrated viewing and reporting tools. |
| | |
| · | Until the closing and initial integration phases are completed, there
will be no further details or changes regarding the new product roadmap, commercial strategy, or operations. We will keep you informed
as new information becomes available. |
| | |
| · | We want to assure you that there will be no immediate changes to your access or use of SmartMammo™. Your experience remains
our top priority, and you can continue to rely on our support and resources as usual. |
No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation
of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall
be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities
Act”), and otherwise in accordance with applicable law.
Important Information about the Proposed Transaction and Where to
Find It
In connection with the proposed transaction between RadNet, Inc. (“RadNet”)
and iCAD, Inc. (“iCAD”), RadNet plans to file with the Securities and Exchange Commission (“SEC”) a registration
statement on Form S-4 that constitutes a prospectus of RadNet and will also include a proxy statement of iCAD. After the registration
statement has been declared effective, iCAD will mail the proxy statement/prospectus to its stockholders. The proxy statement/prospectus
to be filed with the SEC related to the proposed merger will contain important information about RadNet, iCAD, the proposed transaction
and related matters. RadNet and iCAD may also file other documents with the SEC regarding the proposed transaction. This communication
is not a substitute for the proxy statement/prospectus or any other document which RadNet or iCAD may file with the SEC. Investors
are urged to carefully read the proxy statement/prospectus and other documents to be filed with the SEC (or incorporated by reference
into the proxy statement/prospectus), as well as any amendments or supplements to these documents, in connection with the proposed transaction,
when available, because they will contain important information about the proposed transaction and related matters. Investors will
be able to obtain free copies of the registration statement on Form S-4 and the proxy statement/prospectus (when available), and other
documents filed by RadNet or iCAD with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed
with the SEC by RadNet can be obtained by contacting RadNet’s Investor Relations by telephone at (310) 445-2800 or by mail at 1510
Cotner Avenue, Los Angeles, California 90025. In addition, investors are able to obtain free copies of the documents filed with the SEC
on RadNet’s website at www.radnet.com (which website is not incorporated herein by reference). Copies of the documents filed with
the SEC by iCAD can be obtained by contacting iCAD’s Investor Relations by telephone at (608) 882-5200 or by mail at 2 Townsend
West, Suite 6, Nashua, New Hampshire 03063. In addition, investors are able to obtain free copies of the documents filed with the SEC
on iCAD’s website at www.icadmed.com (which website is not incorporated herein by reference).
Participants in the Solicitation
RadNet, iCAD and their respective directors and executive officers
may be considered participants in the solicitation of proxies from iCAD’s stockholders in connection with the proposed transaction.
Information about the directors and executive officers of RadNet is set forth in its proxy statement for its 2024 annual meeting of stockholders,
which was filed with the SEC on April 26, 2024. Information about the directors and executive officers of iCAD is set forth in its proxy
statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 29, 2024. To the extent holdings of RadNet’s
or iCAD’s securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes
have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4
filed with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect
interests, by security holdings or otherwise, and other information regarding the potential participants in the proxy solicitations, which
may be different than those of RadNet’s stockholders and iCAD’s stockholders generally, will be contained in the proxy statement/prospectus
and other relevant materials to be filed with the SEC regarding the proposed transaction. You may obtain these documents (when they become
available) free of charge through the website maintained by the SEC at http://www.sec.gov and from the investor relations departments
at RadNet or iCAD or from RadNet’s website or iCAD’s website, in each case, as described above.
Forward-Looking Statements
This communication contains certain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as:
“anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,”
“intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,”
“project,” “seek, “should,” “target,” “will” or “would,” the negative
of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated
benefits of the proposed transaction, the impact of the proposed transaction on RadNet’s and iCAD’s business and future financial
and operating results and prospects, the amount and timing of synergies from the proposed transaction and the closing date for the proposed
transaction are based on the current estimates, assumptions and projections of RadNet and iCAD, and are qualified by the inherent risks
and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially
from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s and iCAD’s
control.
Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the
future of RadNet’s and iCAD’s business, future plans and strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s and iCAD’s control. RadNet’s,
iCAD’s and RadNet’s actual results and financial condition following the proposed transaction may differ materially from those
indicated in the forward-looking statements as a result of various factors. None of RadNet, iCAD or any of their respective directors,
executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied
in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results
of operations or financial condition of RadNet or iCAD. Should any risks and uncertainties develop into actual events, these developments
could have a material adverse effect on RadNet’s and iCAD’s businesses, the proposed transaction and the ability to successfully
complete the proposed transaction and realize its expected benefits. Risks and uncertainties that could cause results to differ from expectations
include, but are not limited to: (1) the termination of or occurrence of any event, change or other circumstances that could give rise
to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and timetable,
(2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of iCAD or to satisfy
any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed
transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) the ability to recognize the
anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability of RadNet or iCAD to maintain
relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (4) the ability
of RadNet following the proposed transaction to achieve the synergies contemplated by the proposed transaction or such synergies taking
longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of RadNet following the proposed transaction
to execute successfully its strategic plans, (7) the ability of RadNet following the proposed transaction to promptly and effectively
integrate iCAD into its business, (8) the risk of litigation related to the proposed transaction, (9) the diversion of management’s
time and attention from ordinary course business operations to completion of the proposed transaction and integration matters, (10) the
risk of legislative, regulatory, economic, competitive, and technological changes, (11) risks relating to the value of RadNet’s
securities to be issued in the proposed merger, and (12) the effect of the announcement, pendency or completion of the proposed transactions
on the market price of the common stock of each of RadNet and iCAD. The foregoing review of important factors should not be construed
as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information
concerning risks, uncertainties and assumptions can be found in RadNet’s and iCAD’s respective filings with the SEC, including
the risk factors discussed in RadNet’s and iCAD’s most recent Annual Reports on Form 10-K, as updated by their respective
Quarterly Reports on Form 10-Q and future filings with the SEC, as well as the proxy statement/prospectus to be filed with the SEC in
connection with the proposed transaction.
Forward-looking statements included herein are made only as of the
date hereof and, except as required by applicable law, neither RadNet nor iCAD undertakes any obligation to update any forward-looking
statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct
any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their
entirety by this cautionary statement.
Icad (NASDAQ:ICAD)
Historical Stock Chart
From Apr 2025 to May 2025
Icad (NASDAQ:ICAD)
Historical Stock Chart
From May 2024 to May 2025